I

INNOVATE Corp. (VATE)

NYQ – Real vaqt narxi. Valyuta: USD

12.40

-0.05 (-0.40%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

I

INNOVATE Corp. (VATE)

NYQ – Real vaqt narxi. Valyuta: USD

12.40

-0.05 (-0.40%)

Yopilishda: May 12, 2026, 4:00 PM EDT

27.04.2026

INNOVATE Corp. to Report First Quarter 2026 Results on May 14th

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the first quarter 2026 on Thursday, May 14, 2026, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET.

06.04.2026

INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend

NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), a family of companies providing fully integrated steel construction services, and an operating subsidiary of INNOVATE, will pay a cash dividend of approximately $3 million, or $0.78 per share, on April 28, 2026 to DBMG's stockholders of record at the close of business on April 13, 2026. As the largest stockholder of DBMG, INNOVATE expects to receive approximately $2.7 million of the total $3 million dividend payout. INNOVATE's individual stockholders are not eligible to receive the cash dividend.

31.03.2026

MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, and an equity method investment of INNOVATE, announced receipt of European Union (EU) CE Mark certification under the EU Medical Device Regulation (MDR) for its TGFR™ Monitor and TGFR™ Reusable Sensor. The certification confirms that the Monitor and Sensor have met the robust safety, quality, and performance standards required under the EU MDR 2017/745.

26.03.2026

INNOVATE Corp. (VATE) Q4 2025 Earnings Call Prepared Remarks Transcript

26.03.2026

INNOVATE Corp. Announces Fourth Quarter and Full Year 2025 Results

- Infrastructure: NYC and Western markets continue to demonstrate positive project momentum - - Life Sciences: R2 Secures 600‑System Commitment in China - - Spectrum: Recent network launches set to deliver benefits beginning in 2026 -

16.03.2026

INNOVATE Corp. to Report Fourth Quarter and Full Year 2025 Results on March 26th

NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the fourth quarter and full year 2025 on Thursday, March 26, 2026, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET.

10.02.2026

Transdermal GFR Article Recognized as One of Five 2025 Editors' Choice Articles by Journal of the American Society of Nephrology (JASN)

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, in which INNOVATE owns a 44.7% equity interest, announced that the peer-reviewed transdermal GFR measurement article published in the Journal of the American Society of Nephrology (JASN) has been recognized as one of five 2025 Editor's Choice articles.1

Videolar

No Data

There is no data to display

Press-relizlar

06.04.2026

INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend

NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), a family of companies providing fully integrated steel construction services, and an operating subsidiary of INNOVATE, will pay a cash dividend of approximately $3 million, or $0.78 per share, on April 28, 2026 to DBMG's stockholders of record at the close of business on April 13, 2026. As the largest stockholder of DBMG, INNOVATE expects to receive approximately $2.7 million of the total $3 million dividend payout. INNOVATE's individual stockholders are not eligible to receive the cash dividend.

31.03.2026

MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, and an equity method investment of INNOVATE, announced receipt of European Union (EU) CE Mark certification under the EU Medical Device Regulation (MDR) for its TGFR™ Monitor and TGFR™ Reusable Sensor. The certification confirms that the Monitor and Sensor have met the robust safety, quality, and performance standards required under the EU MDR 2017/745.

26.03.2026

INNOVATE Corp. Announces Fourth Quarter and Full Year 2025 Results

- Infrastructure: NYC and Western markets continue to demonstrate positive project momentum - - Life Sciences: R2 Secures 600‑System Commitment in China - - Spectrum: Recent network launches set to deliver benefits beginning in 2026 -

10.02.2026

Transdermal GFR Article Recognized as One of Five 2025 Editors' Choice Articles by Journal of the American Society of Nephrology (JASN)

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, in which INNOVATE owns a 44.7% equity interest, announced that the peer-reviewed transdermal GFR measurement article published in the Journal of the American Society of Nephrology (JASN) has been recognized as one of five 2025 Editor's Choice articles.1

Search stocks

INNOVATE Corp. (VATE)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

INNOVATE Corp. (VATE)

INNOVATE Corp. to Report First Quarter 2026 Results on May 14th

INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend

MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation

INNOVATE Corp. (VATE) Q4 2025 Earnings Call Prepared Remarks Transcript

INNOVATE Corp. Announces Fourth Quarter and Full Year 2025 Results

INNOVATE Corp. to Report Fourth Quarter and Full Year 2025 Results on March 26th

Transdermal GFR Article Recognized as One of Five 2025 Editors' Choice Articles by Journal of the American Society of Nephrology (JASN)

Videolar

No Data

Press-relizlar

INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend

MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation

INNOVATE Corp. Announces Fourth Quarter and Full Year 2025 Results

Transdermal GFR Article Recognized as One of Five 2025 Editors' Choice Articles by Journal of the American Society of Nephrology (JASN)